AEON Biopharma Holds Meeting With FDA for Botox Biosimilar

By Kelly Cloonan

 

AEON Biopharma met with the Food and Drug Administration regarding its biosimilar for Botox and plans to comment on the meeting after receiving official minutes.

The biopharmaceutical company said Wednesday it held a scheduled BPD Type 2a meeting, which is meant to focus specifically on a narrow set of issues. The meeting aimed to review AEON's analytical development plan and initial data supporting biosimilarity, AEON said in November.

The company expects the minutes to inform its next steps for the development of ABP-450, Chief Executive Rob Bancroft said. It is seeking accelerated and full-label U.S. market entry for ABP-450.

"The completion of our BPD Type 2a meeting with FDA represents an important procedural milestone," Bancroft said.

 

Write to Kelly Cloonan at kelly.cloonan@wsj.com

 

(END) Dow Jones Newswires

January 21, 2026 17:01 ET (22:01 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center